ライフサイエンスコーパス: oral glucose tolerance test

1 cases were diagnosed (49.1% on the basis of oral glucose tolerance test).

2 changes in portal insulin (as measured by an oral glucose tolerance test).

3 c insulin extraction from a mixed-meal or an oral glucose tolerance test).

4 glycemia (glucose area under the curve in an oral-glucose-tolerance test).

5 le, and 2-hour glucose was measured after an oral glucose tolerance test.

6 ce or impaired fasting glucose determined by oral glucose tolerance test.

7 sulin concentrations were measured during an oral glucose tolerance test.

8 llary blood glucose test, and a confirmatory oral glucose tolerance test.

9 glucose homeostasis measured by means of an oral glucose tolerance test.

10 All subjects had a standard oral glucose tolerance test.

11 with insulin and glucose levels during a 3-h oral glucose tolerance test.

12 Subjects were categorized based on a 75-g oral glucose tolerance test.

13 relatively normal glucose disposal during an oral glucose tolerance test.

14 ls and improved glycemic excursion during an oral glucose tolerance test.

15 tion (JDF) units or more, and a non-diabetic oral glucose tolerance test.

16 s obtained in the fasting state or during an oral glucose tolerance test.

17 (I0, I120) concentrations obtained during an oral glucose tolerance test.

18 viously undiagnosed diabetes, 4.7%) using an oral glucose tolerance test.

19 ose area (glucose AUC) during the 2 h of the oral glucose tolerance test.

20 asured after an overnight fast and during an oral glucose tolerance test.

21 ed glucose tolerance after oral dosing in an oral glucose tolerance test.

22 of the measures assessed by using a standard oral glucose tolerance test.

23 C-glucose) in the basal state and during an oral glucose tolerance test.

24 eversal of diabetes; mice were then given an oral glucose tolerance test.

25 51 and 629 women, respectively, completed an oral glucose tolerance test.

26 ncentration also increases in response to an oral glucose tolerance test.

27 se-tolerance status was obtained from a 75 g oral glucose-tolerance test.

28 or glucose and insulin were assessed with an oral-glucose-tolerance test.

29 fasting insulin resistance index and with an oral-glucose-tolerance test.

30 0.0011), and 120 min (P = 0.0007) during the oral-glucose-tolerance test.

31 SD age: 21 +/- 11 y) in conjunction with an oral-glucose-tolerance test.

32 t a 5-y follow-up visit was assessed with an oral-glucose-tolerance test.

33 assessed by using the Matsuda method from an oral-glucose-tolerance test.

34 linemic-euglycemic clamp and intravenous and oral glucose tolerance tests.

35 16.6 mumol/L v 131.7 mumol/L; P = 0.09), and oral glucose tolerance tests.

36 Insulin kinetics were calculated from oral glucose tolerance tests.

37 Participants were diagnosed by 75 g oral glucose-tolerance tests.

38 diabetes were verified by record tracing and oral-glucose-tolerance tests.

39 a low-fat diet were genotyped and underwent oral-glucose-tolerance tests.

40 Diabetes status was assessed by using oral-glucose-tolerance tests.

41 The latter is detected by oral glucose tolerance testing.

42 hropometry, and plasma glucose levels during oral glucose tolerance testing.

43 ea under the curve for glucose during 2-hour oral glucose tolerance testing.

44 All subjects underwent a two-hour oral glucose-tolerance test (1.75 g [corrected] of gluco

45 ycemia, preferred strategies were the 2-hour oral glucose tolerance test (100% effectiveness; $390 pe

46 spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the

47 Of 1319 people who were screened with an oral glucose tolerance test, 196 (15%) had impaired gluc

48 g therapy at any examination, or with a 75-g oral glucose tolerance test (1980 World Health Organizat

49 o glucose during the first 30 minutes of the oral glucose tolerance test 2 years later.

50 cose tolerance (area under the curve for 3-h oral glucose tolerance test) 28% (P < 0.05), and plasma

51 560887 was significantly associated with the oral glucose tolerance test 30-min incremental insulin r

52 a euglycemic, hyperinsulinemic clamp and an oral glucose tolerance test (75 g) during steady state g

53 rement (DeltaI(30-0)/DeltaG(30-0)) during an oral glucose tolerance test (a surrogate for insulin sec

54 All underwent an oral glucose tolerance test, a liver panel, and a lipid

55 4 and glucose area under the curve during an oral glucose tolerance test (additive model, P = 0.022;

56 y insulin area under the curve (AUC) from an oral glucose tolerance test, aerobic fitness (peak oxyge

57 screening in the early postpartum period via oral glucose tolerance testing after GDM, which is a tim

58 he curve of insulin and glucose after a 75-g oral-glucose-tolerance test after 4 mo of treatment.

59 ting plasma glucose, hemoglobin A1c, and the oral glucose tolerance test all predict diabetic complic

60 d increased fasting plasma insulin during an oral glucose tolerance test (all P < 0.01), as well as a

61 ts and 10 healthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglyce

62 estionnaire, color Doppler echocardiography, oral glucose tolerance test and blood biomarkers analyse

63 d as the suppression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin in

64 were gestational diabetes (diagnosed with an oral glucose tolerance test and by criteria from the Int

65 jection not only improved the response to an oral glucose tolerance test and corrected insulin signal

66 All underwent an oral glucose tolerance test and fasting lipoprotein subc

67 ose tissue biopsy, in addition to metabolic (oral glucose tolerance test and hyperinsulinemic euglyce

68 a, and disposition index were measured after oral glucose tolerance test and isoglycemic IV glucose i

69 All participants underwent a standard oral glucose tolerance test and provided detailed clinic

70 Participants underwent an oral glucose tolerance test and retinal imaging at 26-28

71 o glucose during the first 30 minutes of the oral glucose tolerance test and using the area under the

72 Nine healthy subjects consumed a 150-g oral glucose tolerance test and were infused with 500 pm

73 ant recipients without diabetes underwent an oral glucose tolerance test and were observed until prim

74 insulinemia, by combining microdialysis with oral glucose tolerance tests and euglycemic-hyperinsulin

75 female obese Zucker (fa/fa) rats using both oral glucose tolerance tests and hyperinsulinemic-euglyc

76 nd enhanced suppression of plasma FFA during oral glucose tolerance tests and insulin clamp in obese

77 fied by the WHO diagnostic criteria based on oral glucose-tolerance test and the ADA fasting criteria

78 Diabetes was diagnosed by annual oral-glucose-tolerance testing and semiannual fasting pl

79 asured after an overnight fast and during an oral glucose tolerance test, and abdominal, thoracic, an

80 se in the glucose area under the curve in an oral glucose tolerance test, and AcAc predicted the conv

81 ions, 2-hour glucose concentrations using an oral glucose tolerance test, and an HbA1c level were sim

82 glucose and lipid levels, the results of an oral glucose tolerance test, and blood pressure were use

83 ulation (O-BP) using a clinical examination, oral glucose tolerance test, and gene expression and DNA

84 glucose (G-AUC) area under the curve during oral glucose tolerance test, and the Belfiore and Stumvo

85 um for 4 days, fasted for 48 h, subjected to oral glucose tolerance test, and then allowed to refeed

86 bA1c and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell

87 rwent clinical laboratory testing, including oral glucose tolerance test, and ultrasonographic invest

88 lucose sensitivity) were derived from a 75-g oral glucose tolerance test, and whole-body insulin sens

89 g insulin and glucagon concentrations during oral glucose tolerance test, and, in vitro, by measuring

90 1 linked to 2-h insulin concentration during oral glucose tolerance testing, and 22q12-13 linked to f

91 , a fasting blood glucose measurement, a 2-h oral-glucose-tolerance test, and record linkage to a rei

92 clamp with measurement of glucose turnover; oral glucose tolerance test; and a liver biopsy.

93 hich time they were weighed and underwent an oral glucose-tolerance test annually.

94 ow-up for 2 years that included 2-hour, 75-g oral glucose tolerance testing; anthropometry; and inter

95 Furthermore, the oral glucose tolerance test appears to be a more sensiti

96 were evaluated annually for 4 years with an oral glucose tolerance test, applying American Diabetes

97 es of maternal metabolism obtained during an oral glucose tolerance test at approximately 28 weeks' g

98 054 adults aged 30-74 years who underwent an oral glucose tolerance test at baseline (1976-1980).

99 total body surface area burned, underwent an oral glucose tolerance test at discharge.

100 ucose and insulin will be measured during an oral glucose tolerance test at weeks 0 and 12.

101 insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end.

102 Oral glucose tolerance tests at discharge revealed that

103 15 centers in nine countries underwent 75-g oral glucose-tolerance testing at 24 to 32 weeks of gest

104 Participants (n = 170) underwent a 3-h oral-glucose-tolerance test at 30 wk (95% CI: 25, 33 wk)

105 se, insulin, and C-peptide measured by using oral-glucose-tolerance tests at the end of each diet.

106 RSM with three predonation RFs (oral glucose tolerance test, basal insulin, fasting plas

107 Participants underwent oral glucose tolerance testing based on WHO definitions

108 odel assessment of insulin resistance and an oral glucose tolerance test-based index (Matsuda insulin

109 with euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin re

110 hin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral admin

111 We performed oral glucose-tolerance tests before and after the admini

112 We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral a

113 glucose below 7 mmol/L, 2 hour glucose after oral glucose tolerance test below 11.1 mmol/L, and glyca

114 utcome measures were difference in change in oral glucose tolerance test between the groups and betwe

115 inistered questionnaires, by fasting and 2-h oral-glucose-tolerance test blood glucose measurement at

116 inistered questionnaires; by fasting and 2-h oral-glucose-tolerance-test blood glucose measurement at

117 tes mellitus (i.e., an abnormal result on an oral glucose-tolerance test but a fasting glucose level

118 excursion between the groups of mice during oral glucose tolerance test, but insulin concentrations

119 hour glucose (beta = 0.46, P = 0.00090) post oral glucose tolerance test, but only the latter passed

120 us adipose tissue biopsies were obtained and oral glucose tolerance tests conducted.

121 glucose area under the curve (AUC) during an oral glucose tolerance test, correlated with MFAUp (r=0.

122 lin level, Matsuda index, and area under the oral glucose tolerance test curve (AUC) of insulin.

123 In the independent cohort, only oral glucose tolerance test-derived indexes were associa

124 ting glucose, fasting glucose or insulin, or oral glucose tolerance test-derived measures.

125 mnography, a multiple sleep latency test, an oral glucose tolerance test, determination of body fat b

126 ent standardized metabolic workup, including oral glucose tolerance tests, determination of hemoglobi

127 e and glucose area under the curve on 2-hour oral glucose tolerance test differed across arms (1-way

128 ed insulin sensitivity, show improvements in oral glucose tolerance tests, display reduced adipose ti

129 n CHD at baseline and had > or =2 (mean 4.2) oral glucose tolerance tests during follow-up.

130 ucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin leve

131 ucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin leve

132 Patients were followed up periodically with oral glucose tolerance tests for up to 7 1/2 years.

133 mes were glucose tolerance (measured with an oral glucose tolerance test given after 90 min) and meal

134 y homeostasis model assessment, and 2-h post-oral glucose tolerance test glucose and insulin levels.

135 bese adolescents with high-"normal" 2-h post-oral glucose tolerance test glucose levels display defec

136 ur plasma glucose >/=200 mg/dL during a 75-g oral glucose tolerance test had a definite diagnosis of

137 c ICA positivity had to be confirmed, and an oral glucose tolerance test had to result in nondiabetic

138 tly correlated with glucose responses during oral glucose tolerance testing, HbA1c, beta-cell functio

139 38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.

140 asting or non-fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and

141 enge test (GCT) followed by a 75-gram 2-hour oral glucose tolerance test if GCT result was >/=7.8 mmo

142 In the oral glucose tolerance test, IL-1betaAb-treated CDs-HSD

143 -5.2]) and with 30-min plasma insulin during oral glucose tolerance test in 287 nondiabetic individua

144 ivo activity in rodents and was active in an oral glucose tolerance test in mice following oral admin

145 gnificantly reduced glucose levels during an oral glucose tolerance test in normal mice.

146 ervous system activity at rest and during an oral glucose tolerance test in obese metabolic syndrome

147 creased plasma GLP-1 concentration during an oral glucose tolerance test in rats.

148 proved half-life and glucose tolerance in an oral glucose tolerance test in rodents.

149 efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.

150 and demonstrated blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and h

151 significantly improved glycemic response to oral glucose tolerance tests in CNTF(Ax15)-treated UCP1-

152 sma glucose responses were higher during the oral glucose tolerance tests in patients with IDCM (p <

153 trations during fasting and 2 h after a 75 g oral glucose-tolerance test in participants aged 65-100

154 resistance and sensitivity were defined from oral-glucose-tolerance tests in 86 overweight and obese

155 nsulin and glucose concentrations during the oral-glucose-tolerance test increased significantly afte

156 (P = 0.02), and the fasting insulin and the oral-glucose-tolerance test insulin area under the curve

157 absorptiometry), glucose tolerance (by 75-g oral glucose tolerance test), insulin action (M; by hype

158 were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (

159 receiving neuroleptic medication were given oral glucose tolerance tests involving serial glucose an

160 rves of glucose and insulin levels during an oral glucose tolerance test; levels of low-density lipop

161 icting to identifying IGT/NODAT using 2-hour oral glucose tolerance test (n = 66), fructosamine was t

162 r flowmetry), and glucose metabolism status (oral glucose tolerance test; normal glucose metabolism [

163 persons without diabetes) was determined by oral-glucose-tolerance testing of the sample aged 40-74

164 (including results of a 26-28 week gestation oral glucose tolerance test) of women from the Born in B

165 these autoantibodies (Ab-), had an abnormal oral glucose tolerance test (OGTT) (P = 0.03) before and

166 years from prediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measureme

167 Study participants were phenotyped by an oral glucose tolerance test (OGTT) and an intravenous gl

168 mpared beta-cell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic in

169 s with varying glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insuli

170 20 type 2 diabetic patients received a 75-g oral glucose tolerance test (OGTT) and euglycemic insuli

171 cose tracer and labeled glucose infusion and oral glucose tolerance test (OGTT) before and 6 months a

172 Fasting, 24-h, and oral glucose tolerance test (OGTT) blood glucose, plasma

173 owing glucose beverage consumption during an oral glucose tolerance test (OGTT) for 400 northern Euro

174 litus (GDM) is conventionally confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of

175 venous glucose tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessio

176 , based on insulin levels measured during an oral glucose tolerance test (OGTT) in 552 nondiabetic pa

177 c evaluation of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based

178 on lower (P < 0.05) during the meal than the oral glucose tolerance test (OGTT) in all subgroups rega

179 exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice.

180 as a compound that displayed activity in an oral glucose tolerance test (OGTT) in normal and diabeti

181 fasting and postprandial lipids and after an oral glucose tolerance test (OGTT) in the European Ather

182 All individuals underwent a 75-g oral glucose tolerance test (OGTT) in which we measured

183 ell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period

184 e obtained, in addition to 0-hour and 2-hour oral glucose tolerance test (OGTT) results, with measure

185 We analyzed the results of an oral glucose tolerance test (OGTT) routinely performed b

186 /dl relative to control HF animals during an oral glucose tolerance test (OGTT) such that levels were

187 The aim of this study was to use an oral glucose tolerance test (OGTT) to risk stratify for

188 zed by the following: 1) associations with 5 oral glucose tolerance test (OGTT) traits in 427 nondiab

189 10%) reduced, but the glucose response to an oral glucose tolerance test (OGTT) was not affected.

190 in and glucose were monitored weekly, and an oral glucose tolerance test (OGTT) was performed at stud

191 The 5-hour oral glucose tolerance test (OGTT) was performed to asse

192 h positive O'Sullivan test (POT) results, an oral glucose tolerance test (OGTT) was performed to diag

193 An oral glucose tolerance test (OGTT) was used to evaluate

194 ons of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in indi

195 the insulin-to-glucose ratio (IGR) at 30-min oral glucose tolerance test (OGTT), a frequently used su

196 atched control participants and underwent an oral glucose tolerance test (OGTT), a hypoglycemia quest

197 n areas under the 2-h curve (AUCs) during an oral glucose tolerance test (OGTT), and blood lipids in

198 at reducing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was

199 e in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first betwe

200 by blood glucose and insulin responses to an oral glucose tolerance test (OGTT), insulin sensitivity

201 s with wild-type genotype (CC) underwent 5-h oral glucose tolerance test (OGTT), isoglycemic intraven

202 Herein we describe oral glucose tolerance test (OGTT)-modeled beta-cell fun

203 dices of beta-cell function derived from the oral glucose tolerance test (OGTT).

204 A total of 319 subjects were studied with an oral glucose tolerance test (OGTT).

205 frank diabetes based on the rarely utilized oral glucose tolerance test (OGTT).

206 ging and glucose and insulin responses to an oral glucose tolerance test (OGTT).

207 ears; BMI 29.0 +/- 0.3 kg/m(2)) underwent an oral glucose tolerance test (OGTT).

208 and 2-h insulin concentrations after a 75-g oral glucose tolerance test (OGTT).

209 g) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).

210 se >/= 11.1 mmol/L (>/= 200 mg/dL) during an oral glucose tolerance test (OGTT).

211 ized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).

212 lucose-lowering actions were tested after an oral glucose tolerance test (OGTT).

213 At wk 15, pigs were subjected to an oral glucose tolerance test (OGTT); blood glucose increa

214 nal age at delivery, parity, maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for

215 All subjects were characterized by oral glucose tolerance testing (OGTT) and National Diabe

216 Oral glucose tolerance testing (OGTT) has been mooted as

217 .3 kg/m(2), 66 women, 35 men) underwent 75-g oral glucose tolerance testing (OGTT), body composition

218 All animals underwent oral glucose tolerance testing (OGTT).

219 abetic renal transplant recipients underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (bas

220 after death and who had undergone 2 or more oral glucose tolerance tests (OGTT) using grouped analys

221 pharmacodynamic endpoints were explored with oral glucose tolerance tests (OGTT), serum lipid profile

222 ave 2-h glucose values >11.1 mmol/l on their oral glucose tolerance tests (OGTT).

223 homeostasis by fasting blood glucose and/or oral glucose tolerance tests (OGTT).

224 28; aged 26 +/- 2 y) were tested with a 5-h oral-glucose-tolerance test (OGTT) and a euvolemic, euen

225 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-

226 Serum lipids and fasting and 2-h oral-glucose-tolerance test (OGTT) glucose and insulin c

227 itivity was measured by fasting and 2-h post-oral-glucose-tolerance test (OGTT) insulin, the homeosta

228 g/m(2)) of 22.4 +/- 0.8 were subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days wi

229 ly diagnosed diabetes by 2-h glucose from an oral glucose tolerance test [OGTT] [DM2h], n = 80; newly

230 To examine this possibility, we performed oral glucose tolerance tests (OGTTs) and euglycemic-insu

231 Oral glucose tolerance tests (OGTTs) and frequently samp

232 Oral glucose tolerance tests (OGTTs) and intravenous glu

233 Oral glucose tolerance tests (OGTTs) from differing stat

234 their associations with glucose levels from oral glucose tolerance tests (OGTTs) in pregnancy have n

235 sma glucose was measured every 3 months, and oral glucose tolerance tests (OGTTs) were performed annu

236 subjects with the E/E genotype underwent 5-h oral glucose tolerance tests (OGTTs), graded glucose inf

237 n of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that

238 tralizing antibody was administered prior to oral glucose tolerance tests (OGTTs).

239 Oral-glucose-tolerance tests (OGTTs) were performed befo

240 h measures collected from frequently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29

241 Subjects received a standard 2-h oral glucose tolerance test on the first day and an insu

242 G) ingested a labeled meal and 75 g glucose (oral glucose tolerance test) on separate occasions.

243 definition, despite not requiring the use of oral glucose tolerance testing or measures of IR or micr

244 ept for a reduced insulinemic response to an oral-glucose-tolerance test over time with daily breakfa

245 clinical and anthropometric examinations, an oral glucose tolerance test, overnight urine collection,

246 with glucose area under the curve during an oral glucose tolerance test (P = 0.035 and 0.013, respec

247 consumption (P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10) trended toward be

248 Oral glucose tolerance tests performed during the last w

249 We studied this progression using biennial oral glucose tolerance tests performed in the Baltimore

250 lipids, we performed lipid profiling during oral glucose tolerance testing, pharmacologic interventi

251 d ALT, AST, and GGT in 451 nondiabetic (75-g oral glucose tolerance test) Pima Indians (aged 30 +/- 6

252 rum resistin levels in 113 nondiabetic (75-g oral glucose tolerance test) Pima Indians (ages 29 +/- 7

253 All underwent oral glucose tolerance tests pre-LTx and serially post-L

254 days, fasted overnight, and subjected to an oral glucose tolerance test; protocol 3, fed ad libitum

255 rimester of pregnancy (2-h glucose after the oral glucose tolerance test; r(s) </= -0.21, P < 0.05).

256 is unique because diabetes was determined by oral glucose tolerance testing rather than by self-repor

257 nge in glucose tolerance estimated by a 75-g oral glucose tolerance test result.

258 On the basis of oral glucose tolerance test results, participants were g

259 Oral glucose tolerance tests revealed that male Znt7 KO

260 n in the insulinogenic index derived from an oral glucose tolerance test (risk allele homozygotes hav

261 nd indirect calorimetry), glucose tolerance (oral glucose tolerance test), serum lipid profile, and d

262 In an oral glucose tolerance test, the 0- to 120-min glucose i

263 In the oral glucose tolerance test, the chloroform extract exer

264 However, the glycemic response to oral glucose tolerance testing, the acute insulin respon

265 = 292), and Hispanics (n = 34) underwent an oral glucose tolerance test to assess whole-body insulin

266 ge insulin concentrations were determined by oral-glucose-tolerance test, total body fat by dual-ener

267 ment was associated with the need to perform oral glucose tolerance testing upon study completion, by

268 e levels in healthy adults during a standard oral glucose tolerance test via exhaled VOC analysis.

269 An oral glucose tolerance test was administered at discharg

270 f insulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.

271 Oral glucose tolerance test was considered the gold stan

272 Oral glucose tolerance test was performed within 2 weeks

273 Dakota; blood samples were drawn and a 75-g oral glucose tolerance test was performed.

274 years of age, without diabetes by history or oral glucose tolerance test, was done between 1992 and 1

275 asma glucose and hemoglobin A1c than for the oral glucose tolerance test, we suggest an alternative d

276 sensitivity and rate sensitivity during the oral glucose tolerance test were measured with the model

277 and 2-hour glucose levels measured during an oral glucose tolerance test were used to assess glycemic

278 Oral glucose tolerance tests were administered at the sa

279 od samples were collected in the morning and oral glucose tolerance tests were done in accordance wit

280 Oral glucose tolerance tests were performed annually on

281 Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually.

282 Physical examinations and oral glucose tolerance tests were performed at baseline

283 Modified oral glucose tolerance tests were performed in schizophr

284 Oral glucose tolerance tests were performed in the 43 pa

285 Oral glucose tolerance tests were performed to examine t

286 ed; and (3) peak blood glucose levels during oral glucose tolerance tests were significantly reduced.

287 and 2-h glucose and insulin areas during the oral-glucose-tolerance test were similar across treatmen

288 d hormone concentrations, and results of 3-h oral-glucose-tolerance tests were examined in obese and

289 ulinemic clamp), and glucose tolerance (75-g oral glucose tolerance test) were measured in 55 Pima In

290 ts (5 men), as determined by a standard 75-g oral glucose tolerance test, were recruited to determine

291 ulin clearance were estimated by means of an oral glucose tolerance test, whereas peripheral insulin

292 control participants underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood

293 A total of 1,437 individuals underwent an oral glucose tolerance test with measurements of circula

294 of NAFLD patients underwent liver biopsy, an oral glucose tolerance test with minimal model analysis

295 okines, and cytokeratin-18 fragments, and an oral glucose tolerance test with minimal model analysis

296 se during the first 30 min and 60 min of the oral glucose tolerance test with the gastric half-emptyi

297 Oral glucose tolerance testing with glucose, insulin, an

298 In oral glucose tolerance tests with diet-induced obese mic

299 NAFLD patients underwent a liver biopsy, an oral-glucose-tolerance test with minimal model analysis

300 tly associated with glucose levels during an oral glucose tolerance test, with the same SNP (rs642734